Notable Labs, Ltd. (NTBL)
(Delayed Data from NSDQ)
$0.53 USD
+0.04 (8.41%)
Updated Aug 8, 2024 01:35 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
NTBL 0.53 +0.04(8.41%)
Will NTBL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NTBL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NTBL
Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now
Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock?
NTBL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NTBL
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Notable Labs Advances with Phase 2 Trial for Volasertib
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Notable Labs receives FDA clearance to proceed further with volasertib study
Notable Labs receives FDA clearance to proceed with Volasertib phase 2 study